I.G. Investment Management’s Arbutus Biopharma ABUS Stock Holding History

I.G. Investment Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-250,000	Closed	-$870K	–	891
2016 Q2	$870K	Buy	+250,000	New	+$1.06M	﹤0.01%	675
2015 Q1	–	Sell	-63,750	Closed	-$976K	–	859
2014 Q4	$976K	Buy	+63,750	New	+$1.1M	﹤0.01%	641
2014 Q3	–	Sell	-63,750	Closed	-$831K	–	843
2014 Q2	$831K	Hold	63,750	–	–	﹤0.01%	662
2014 Q1	$1.38M	Hold	63,750	–	–	0.01%	510
2013 Q4	$507K	Hold	63,750	–	–	﹤0.01%	692
2013 Q3	$445K	Sell	63,750 -86,250	-58%	-$475K	﹤0.01%	705
2013 Q2	$691K	Buy	+150,000	New	+$710K	﹤0.01%	627

Other funds holding ABUS

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

I.G. Investment Management's ABUS Position: Q3 2016 in Review

I.G. Investment Management sold out of Arbutus Biopharma (ABUS) in Q3 2016, closing a stake of 250,000 shares — an estimated $870K sold.

I.G. Investment Management first reported a position in ABUS in Q2 2013 and held it in 7 quarters. The position peaked at $1.38M in Q1 2014. 48 funds tracked by Wall St. Rank hold ABUS as of Q3 2016.

I.G. Investment Management reported no remaining Arbutus Biopharma position as of Q3 2016 after selling out during the quarter.
I.G. Investment Management sold 250,000 Arbutus Biopharma shares in Q3 2016, an estimated $870K.
I.G. Investment Management first reported a position in Arbutus Biopharma in Q2 2013 and held it in 7 quarters.
I.G. Investment Management's Arbutus Biopharma position peaked at $1.38M in Q1 2014.
48 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2016.

Based on I.G. Investment Management's 13F filing for Q3 2016, filed 14 Nov 2016.